Research Use Disclaimer

You must be 21 or older. Agree to the following terms before accessing product information and pricing.

Research Use Policy Summary

You are 21 years of age or older
All products sold exclusively for laboratory research purposes
Products are not intended for human consumption, diagnosis, or therapeutic use
Purchasers must be qualified researchers or licensed professionals
These products have not been evaluated or approved by the FDA
All sales are final and subject to our research use terms

For laboratory research use only. Not for human or veterinary consumption, diagnostic use, therapeutic use, or clinical use.

Read full Research Use Disclaimer (opens in new tab) →

Product Usage Notice · This product is intended strictly for research and laboratory use only. It is designated for in vitro testing and experimental purposes. Any use involving human or animal consumption is prohibited by law. All information provided on this website is for educational purposes only. This product must only be handled by licensed, qualified professionals. It is not intended for use as a drug, food, or cosmetic, and must not be misused, mislabeled, or misrepresented as such. Read full Research Use Policy →

Compound Information

Technical specifications

Molecular Profile

What Is Ipamorelin?

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist, studied for its ability to stimulate GH release with minimal effect on cortisol or prolactin levels.

Type: Peptide
CAS Number: 170851-70-4
Molecular Weight: 711.86 g/mol
Amino Acids: 5 residues
Sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2
Formula: C38H49N9O5

PubChem Database

IPAMORELIN · 1998

Ipamorelin, the First Selective Growth Hormone Secretagogue European Journal of Endocrinology Foundational paper establishing ipamorelin as a selective GHS-R1a agonist. Unlike GHRP-2 and GHRP-6, ipamorelin does not stimulate ACTH or cortisol, making it uniquely selective.

View Study

IPAMORELIN · 1999

Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in receptor pharmacology literature Pharmaceutical Research Published pharmacokinetic study characterizing GH release kinetics and half-life profile of ipamorelin. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study

IPAMORELIN · 1999

Ipamorelin Induces Longitudinal Bone Growth in Rats Growth Hormone & IGF Research Ipamorelin concentration-dependently increased longitudinal bone growth rate from 42 to 52 µm/day with pronounced concentration-dependent effects on growth pathway readouts in adult female rats.

View Study

IPAMORELIN · 1998

Ipamorelin, a New Growth-Hormone-Releasing Peptide, Induces Growth Hormone Release via Hypothalamic GHS-R1a in Conscious Rats Growth Hormone & IGF Research Ipamorelin demonstrated potent, concentration-dependent GH release without affecting ACTH, cortisol, prolactin, FSH, LH, or TSH — establishing it as the most selective growth hormone secretagogue known.

View Study

IPAMORELIN · 2000

The GH Secretagogue Ipamorelin Counteracts Glucocorticoid-Induced Decrease in Bone Formation of Adult Rats Growth Hormone & IGF Research Ipamorelin changed dexamethasone-induced bone loss in adult rats, tracking bone formation markers and trabecular bone mineral density through sustained GH/IGF-I axis stimulation.

View Study

IPAMORELIN · 2007

Study of Ghrelin-Receptor Prokinetic Pathway Markers by Ipamorelin: A Novel Growth Hormone Secretagogue Neurogastroenterology & Motility Published pharmacology literature describing ipamorelin as a ghrelin receptor-mediated prokinetic tool compound for gastrointestinal motility pathway research in controlled experimental models.

View Study